行情

NSPR

NSPR

INSPIREMD
AMEX

实时行情|Nasdaq Last Sale

0.6010
-0.0185
-2.99%
已收盘, 17:16 04/02 EDT
开盘
0.6716
昨收
0.6195
最高
0.6940
最低
0.5900
成交量
1.55万
成交额
--
52周最高
7.75
52周最低
0.4800
市值
260.77万
市盈率(TTM)
-0.0830
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NSPR价格均价为2.000,最高价位2.000,最低价为2.000。

EPS

NSPR 新闻

更多
  • 沪指周跌0.3% 原油暴涨抵消失业潮利空、隔夜美股收高
  • 新浪财经 · 1小时前
  • 两家空头为瑞幸咖啡“隔空交锋” 浑水最终赢了Citron
  • 新浪财经 · 1小时前
  • 自爆22亿元业绩造假后 瑞幸今天的订单“爆了”
  • 界面新闻 · 2小时前
  • 特朗普可能不靠谱,但欧佩克+下周会议基本确定,布油涨超7%
  • 新浪财经综合 · 2小时前

所属板块

医疗设备、用品及经销
+2.77%
医疗设备和用品
+3.33%

热门股票

代码
价格
涨跌幅

NSPR 简况

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
展开

微牛提供InspireMD Inc(AMEX-NSPR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NSPR股票新闻,以帮助您做出投资决策。